New drug trial hopes to tame rare blood cancers

NCT ID NCT07008118

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times

Summary

This early-stage study tests a new drug, INCA035784, for safety in 120 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Participants must have a specific gene mutation (CALR) and have tried other treatments. The main goal is to check for side effects, not to cure the disease. The study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica
NOT_YET_RECRUITING

Florence, 50134, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
NOT_YET_RECRUITING

Bergamo, 24127, Italy
Centro Ricerche Cliniche Di Verona
NOT_YET_RECRUITING

Verona, 37134, Italy
Cliniques Universitaires Saint-Luc
NOT_YET_RECRUITING

Brussels, 01200, Belgium
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Fondazione Irccs Ca Granda Ospedale Maggiore
NOT_YET_RECRUITING

Milan, 20122, Italy
Huntsman Cancer Institute At University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Icahn School of Medicine At Mount Sinai
RECRUITING

New York, New York, 10029, United States
Johns Hopkins University
NOT_YET_RECRUITING

Baltimore, Maryland, 21287, United States
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, 06009, Australia
Macquarie University Hospital
RECRUITING

Sydney, New South Wales, 02109, Australia
Mayo Clinic Hospital
NOT_YET_RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic-Florida
NOT_YET_RECRUITING

Jacksonville, Florida, 32224, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 05000, Australia
South Austin Medical Center
RECRUITING

Austin, Texas, 78704, United States
Stanford University
RECRUITING

Palo Alto, California, 94304, United States
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 03004, Australia
Universitaetsklinikum Dresden
NOT_YET_RECRUITING

Dresden, 01307, Germany
Universitair Ziekenhuis Gent
NOT_YET_RECRUITING

Ghent, 09000, Belgium
Universitaire Ziekenhuizen Leuven
NOT_YET_RECRUITING

Leuven, 03000, Belgium
Universitatsklinikum Halle (Saale)
NOT_YET_RECRUITING

Halle, 06120, Germany
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
NOT_YET_RECRUITING

Mainz, 55131, Germany
University of Chicago Medical Center
NOT_YET_RECRUITING

Chicago, Illinois, 60637, United States
University of North Carolina At Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood
NOT_YET_RECRUITING

Dallas, Texas, 75235, United States

Conditions

Explore the condition pages connected to this study.

MYELOPROLIFERATIVE NEOPLASMS MYELOPROLIFERATIVE NEOPLASMS